Vistagen Therapeutics, Inc. (VTGN) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Vistagen Therapeutics, Inc. (VTGN) closed at USD 0.21 on 2026-10-14, a change of -94.8 % over the past year, with a market capitalization of USD 9.45M.

Vistagen Therapeutics, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Vistagen Therapeutics, Inc. key figures

Previous close

USD 0.21 (2026-10-14)

1-year change

-94.8 %

Market cap

USD 9.45M

Enterprise value

USD -21.49M

P/E ratio (trailing)

-0.13

P/E ratio (forward)

-0.14

EPS (trailing)

-1.65

EPS (forward)

-1.54

PEG ratio

n/a

Price to book

0.39

Revenue growth

504.9 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.13

Employees

41

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Vistagen Therapeutics, Inc.

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase IIa clinical trial to treat major depressive disorder. It also develops refisolone, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial for the treatment of vasomotor symptoms, including hot flashes due to menopause, premenstrual dysphoric disorder, and other women's health disorders; PH15, an investigational pherine nasal spray, which is in Phase IIa clinical trial for the treatment to improve cognitive impairment caused by mental fatigue disorders; PH284, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase IIa clinical trial to treat loss of appetite associated with chronic disorders, such as cancer cachexia; and AV-101, an oral prodrug that targets N-methyl-D-aspartate receptor in the brain for treating depression and neurological disorders. It has a license and collaboration agreement with AffaMed Therapeutics, Inc. to develop, manufacture, and commercialize fasedienol for multiple anxiety-related disorders. Vistagen Therapeutics, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Vistagen Therapeutics, Inc. and compare it with other stocks.